ALT250509P3000
- 0.00
- 0.000.00%
Altimmune Newsroom
Earnings Preview: Altimmune to Report Financial Results on May 13
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
10 Health Care Stocks Whale Activity In Today's Session
After Losing 21% in the Past Year, Altimmune, Inc. (NASDAQ:ALT) Institutional Owners Must Be Relieved by the Recent Gain
What's Going On With Altimmune (ALT) Stock Today?
Altimmune to Present at Upcoming EASL International Liver Congress 2025
Altimmune to Participate in the Citizens Life Sciences Conference
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Altimmune (ALT)
$ALT Stock Is up 2% Today. Here's What We See in Our Data.
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
Viking, Structure, Metsera on a Tear as Pfizer Drops Obesity Pill
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Altimmune's US$42m Market Cap Fall Books Insider Losses
Altimmune Management to Meet With Piper Sandler
8 Analysts Assess Altimmune: What You Need To Know
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Cue Biopharma (CUE) and Atricure (ATRC)
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Altimmune's Strategic Positioning and Promising Future in Obesity and MASH Treatment Markets